Posted on 4/25/17
Merck: Strong Research And Bolt-On Acquisitions
Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE) and Merck & Co. (NYSE:MRK) comprise 10% of my portfolio. I briefly highlighted JNJ in last month's portfolio review. I . . .
Posted on 4/25/17
Better Buy: Amgen Inc. vs. Pfizer
Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) are "frenemies" in the pharmaceutical world. The two companies partner on blockbuster autoimmune disease drug Enbrel, but could be future rivals . . .
Posted on 4/25/17
Were Johnson & Johnson's Earnings Really That Bad?
Johnson & Johnson (NYSE:JNJ)is one of the biggest companies in the world, and certainly the biggest pharma on the market, with over 250 sub-companies making up . . .
Posted on 4/25/17
Data Diagnostics Wins Gold at the 30th Annual Edison Awards
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) announced that Data Diagnostics®, a point-of-care health analytics technology, won a gold award in the Health and Wellness—Patient . . .
Posted on 4/25/17
Novartis Expands Global Collaboration with Amgen
Novartis today announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine. This agreement builds on . . .
Posted on 4/25/17
Diaceutics Signs Multi-Million-Dollar Partnership with BioReference Laboratories
PARSIPPANY, N.J.--(BUSINESS WIRE)--Diaceutics, the data insights and solutions company enabling better patient testing globally, today announces a five-year partnership with NJ-based BioReference Laboratories. The exclusive partnership . . .
Posted on 4/25/17
ShopRite Joins Aetna’s Preferred Medicare Pharmacy Network
KEASBEY, N.J. & HARTFORD, Conn.--(BUSINESS WIRE)--ShopRite and Aetna (NYSE: AET) today announced ShopRite has joined Aetna’s national network of preferred pharmacies. Effective immediately, Aetna Medicare members . . .
Posted on 4/24/17
Merck Leads Rivals In Novel Drug Approvals
The annual tally of novel drug approvals is often taken as a barometer of productivity, and an analysis of the companies most responsible for bringing these . . .
Posted on 4/24/17
Johnson & Johnson: Modest Price Decline Presents Buying Opportunity
Written by Nicholas McCullum for Sure Dividend on April 21, 2017.Johnson & Johnson (NYSE:JNJ) is one of the most stable businesses around.The company’s statistics are impressive: . . .
Posted on 4/24/17
3 Things Johnson & Johnson Didn't Tell You in Its Q1 Earnings Update
Johnson & Johnson (NYSE:JNJ) reported its 2017 first-quarter results on Tuesday morning. The healthcare giant again beat earnings estimates, just as it did throughout 2016.Investors heard . . .
Posted on 4/24/17
Better Buy: AbbVie Inc. vs. Pfizer
Dividend-paying pharma stocks can generate sky-high returns for investors with a long-term outlook. This particular sub-sector, after all, is starting to benefit from favorable tailwinds that . . .
Posted on 4/24/17
Edison Awards Recognize Ortho Clinical Diagnostics for Outstanding Product Innovation
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it has been awarded an Edison Award™ for Global Product Innovation, for . . .
Posted on 4/21/17
Pfizer: Relatively High Yield Healthcare Blue Chip
Pfizer and its DividendPfizer (NYSE:PFE) was on my watch list back in 2009 when they cut the dividend from $.32 per quarter in Q1 to $.16 . . .
Posted on 4/21/17
Better Buy: Verizon Communications Inc. vs. Johnson & Johnson
Dividends aren't sexy but they are effective. While companies that offer regular payouts aren't likely to triple in value in any given year, dividends are the . . .
Posted on 4/21/17
Onconova Therapeutics Announces Proposed Public Offering of Common Stock
NEWTOWN, Pa., April 20, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug . . .
Posted on 4/21/17
Interpace Diagnostics Eliminates Long Term Secured Debt
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and . . .
Posted on 4/21/17
Zillion Health and Vidyo Aim to Simplify Patient Engagement
HACKENSACK, N.J. & NORWALK, Conn.--(BUSINESS WIRE)--Leading video collaboration technology provider Vidyo today announced a new partner in population health management, Zillion® Health, a cutting-edge patient engagement . . .
Posted on 4/21/17
FamilyWize Launches "Healthy You, Happy Orlando" Campaign
Participants can enter to win $1,000 for themselves and a $10,000 donation to a local charityFamilyWize Community Service Partnership announced today the launch of "Healthy You, . . .
Posted on 4/20/17
J&J Now Too Cheap To Its Peers To Ignore
BackgroundFar and away the world's largest healthcare company, and with many or most of its consumer brands also medicines or health-related, Johnson & Johnson (NYSE:JNJ) would . . .
Posted on 4/20/17
Celgene: The Next Dominant Pharma Company - Celgene Corporation
According to Centers for Medicare & Medicaid Services, prescription drug spending is projected to grow at an average rate of 6.3% per year through 2025. Given . . .
Posted on 4/20/17
5 Ways Johnson & Johnson Disappointed Us With Its Q1 Results
On Tuesday morning, healthcare conglomerate Johnson & Johnson (NYSE:JNJ) released its much-anticipated first-quarter earnings results. Based on the reaction -- a nearly $4 move lower, which . . .
Posted on 4/20/17
Johnson & Johnson: Was The Sell-Off Justified?
Image creditJohnson & Johnson (NYSE:JNJ) is a stock I've oscillated on in the past. I've long thought it to be expensive - owed to the power . . .
Posted on 4/19/17
Edge Therapeutics Announces $18 Million Registered Direct Offering of Common Stock
BERKELEY HEIGHTS, N.J., April 19, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, . . .
Posted on 4/19/17
Johnson & Johnson 2017 Q1 - Results - Earnings Call Slides
The following slide deck was published by Johnson & Johnson in conjunction with their 2017 Q1 earnings call. 117READ FULL ARTICLE HERE
Posted on 4/19/17
Is Johnson & Johnson At The Mercy Of The Business Cycle?
While signs of stress appear evident in the equity markets, with the VIX index hovering around six-month highs and interest rates falling to the 2.2% area, . . .

